Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Pietrantonio

Showing results (171-180 of 323) with videos related to

Pageof 33
Sort By:
Eclinicalmedicine|October 25, 2023
Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendationsAlberto Giovanni Leone, Raffaella Casolino, Dario Trapani, et al.
The Oncologist|April 10, 2020
Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future TrialsSalvatore Corallo, Giovanni Fucà, Federica Morano, et al.
BMC Cancer|July 24, 2020
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancerCarlotta Antoniotti, Beatrice Borelli, Daniele Rossini, et al.
European Journal of Cancer (Oxford, England : 1990)|October 25, 2025
Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trialEleonora Cristarella, Margherita Ambrosini, Massimo Di Maio, et al.
European Journal of Cancer (Oxford, England : 1990)|September 26, 2020
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord OvestRoberto Moretto, Daniele Rossini, Gemma Zucchelli, et al.
The Oncologist|April 14, 2026
Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancerVincenzo Nasca, Margherita Ambrosini, Julien Taieb, et al.
British Journal of Cancer|November 23, 2021
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino studyPaolo Manca, Salvatore Corallo, Sara Lonardi, et al.
The Oncologist|August 20, 2025
First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancerVincenzo Nasca, Gabriele Tinè, Julien Taieb, et al.
The Oncologist|December 18, 2020
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based AnalysisFilippo Pietrantonio, Giovanni Fucà, Daniele Rossini, et al.
BMC Cancer|June 11, 2017
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO groupChiara Cremolini, Federica Marmorino, Fotios Loupakis, et al.
Pageof 33

Showing results (171-180 of 323) with videos related to

Sort By:
Pageof 33
Eclinicalmedicine|October 25, 2023
Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendationsAlberto Giovanni Leone, Raffaella Casolino, Dario Trapani, et al.
The Oncologist|April 10, 2020
Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future TrialsSalvatore Corallo, Giovanni Fucà, Federica Morano, et al.
BMC Cancer|July 24, 2020
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancerCarlotta Antoniotti, Beatrice Borelli, Daniele Rossini, et al.
European Journal of Cancer (Oxford, England : 1990)|October 25, 2025
Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trialEleonora Cristarella, Margherita Ambrosini, Massimo Di Maio, et al.
European Journal of Cancer (Oxford, England : 1990)|September 26, 2020
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord OvestRoberto Moretto, Daniele Rossini, Gemma Zucchelli, et al.
The Oncologist|April 14, 2026
Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancerVincenzo Nasca, Margherita Ambrosini, Julien Taieb, et al.
British Journal of Cancer|November 23, 2021
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino studyPaolo Manca, Salvatore Corallo, Sara Lonardi, et al.
The Oncologist|August 20, 2025
First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancerVincenzo Nasca, Gabriele Tinè, Julien Taieb, et al.
The Oncologist|December 18, 2020
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based AnalysisFilippo Pietrantonio, Giovanni Fucà, Daniele Rossini, et al.
BMC Cancer|June 11, 2017
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO groupChiara Cremolini, Federica Marmorino, Fotios Loupakis, et al.
Pageof 33